SOP for Telemedicine Visits and Remote AE Reporting

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-telemedicine-visits-and-remote-ae-reporting”
},
“headline”: “SOP for Telemedicine Visits and Remote AE Reporting”,
“description”: “This SOP describes standardized procedures for conducting telemedicine visits and remote adverse event (AE) reporting in clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements while protecting subject privacy and data integrity.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Published on 22/12/2025

Standard Operating Procedure for Telemedicine Visits and Remote AE Reporting

SOP No.	CR/OPS/124/2025
Supersedes	NA
Page No.	1 of 68
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Table of Contents

Purpose

The purpose of this SOP is to define standardized procedures for implementing telemedicine visits and remote adverse event (AE) reporting in

clinical trials. It enables subject safety, data integrity, and regulatory compliance while facilitating decentralized and hybrid trial designs.

Scope

This SOP applies to sponsors, investigators, site staff, CROs, and regulatory teams involved in clinical trials using telemedicine and remote AE reporting solutions. It covers teleconsultation procedures, remote AE identification, documentation, reporting, privacy safeguards, and inspection readiness.

Responsibilities

Sponsor: Ensures validated telemedicine platforms and oversees remote AE reporting compliance.
Investigator: Conducts teleconsultations, assesses AEs, and ensures accurate documentation.
Site Staff: Support telemedicine visits and assist subjects in AE reporting.
CRO: Monitors telemedicine compliance and audits remote AE documentation.
QA: Audits telemedicine and AE reporting systems for compliance.
EC/IRB: Reviews and approves telemedicine procedures and AE reporting processes.

Accountability

The Principal Investigator is accountable for the conduct of telemedicine visits and AE reporting accuracy. The Sponsor is accountable for overall oversight and compliance with global regulations.

Procedure

1. Platform Validation
1.1 Use telemedicine platforms validated for security, privacy, and data retention.
1.2 Ensure compliance with HIPAA, GDPR, and FDA Part 11.
1.3 Document validation in Telemedicine Platform Log (Annexure-1).

2. Telemedicine Visits
2.1 Schedule visits according to protocol timelines.
2.2 Obtain subject consent for teleconsultation.
2.3 Conduct visits via secure video/audio systems.
2.4 Document visit details in Telemedicine Visit Log (Annexure-2).

3. Remote AE Identification
3.1 Instruct subjects to report AEs via phone, email, or telemedicine platform.
3.2 Investigators review and classify AE severity and causality.
3.3 Document in Remote AE Log (Annexure-3).

4. AE Documentation and Reporting
4.1 Record AE details in eCRF within 24 hours of identification.
4.2 Report SAEs to sponsor within regulatory timelines.
4.3 Maintain AE Notification Log (Annexure-4).

5. Data Privacy
5.1 Ensure encrypted communication and secure storage.
5.2 Maintain confidentiality per GDPR/HIPAA.
5.3 Document in Data Privacy Log (Annexure-5).

6. Training
6.1 Train investigators and staff in telemedicine workflows.
6.2 Provide subjects with instructions for reporting AEs remotely.
6.3 Record in Training Log (Annexure-6).

7. Inspection Readiness
7.1 Maintain inspection-ready telemedicine and AE reporting records.
7.2 Document mock inspections in Inspection Readiness Log (Annexure-7).

Abbreviations

SOP: Standard Operating Procedure
AE: Adverse Event
SAE: Serious Adverse Event
CRO: Contract Research Organization
QA: Quality Assurance
EC/IRB: Ethics Committee/Institutional Review Board
GDPR: General Data Protection Regulation
HIPAA: Health Insurance Portability and Accountability Act
TMF: Trial Master File
ISF: Investigator Site File
FDA: Food and Drug Administration
EMA: European Medicines Agency
CDSCO: Central Drugs Standard Control Organization

Documents

Telemedicine Platform Log (Annexure-1)
Telemedicine Visit Log (Annexure-2)
Remote AE Log (Annexure-3)
AE Notification Log (Annexure-4)
Data Privacy Log (Annexure-5)
Training Log (Annexure-6)
Inspection Readiness Log (Annexure-7)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Clinical Operations Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: Telemedicine Platform Log

Date	Platform	Validation Status	Reviewed By
01/09/2025	MediConnect v2.1	Validated	QA Officer

Annexure-2: Telemedicine Visit Log

Date	Subject ID	Visit Type	Investigator	Status
02/09/2025	S101	Follow-up	Investigator	Completed

Annexure-3: Remote AE Log

Date	Subject ID	AE Reported	Severity	Investigator
03/09/2025	S101	Headache	Mild	Investigator

Annexure-4: AE Notification Log

Date	Subject ID	AE	Notified To	Status
04/09/2025	S101	Headache	Sponsor	Reported

Annexure-5: Data Privacy Log

Date	System	Measure	Reviewed By	Status
05/09/2025	MediConnect v2.1	End-to-end Encryption	QA Officer	Compliant

Annexure-6: Training Log

Date	Staff Name	Training Topic	Trainer	Status
06/09/2025	Site Nurse	Telemedicine AE Reporting	Investigator	Completed

Annexure-7: Inspection Readiness Log

Date	Agency	Simulation	Performed By	Status
07/09/2025	FDA	Mock Inspection	QA Team	Completed

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Operations

For more SOPs visit: Pharma SOP